Investor Alert: Kaplan Fox Announces Investigation Of Intra-Cellular Therapies, Inc.

NEW YORK, May 2, 2017

On May 1, 2017 before the market opened, Intra-Cellular Therapies issued a press release reporting that as part of its ongoing dialogue with the U.S. Food and Drug Administration (FDA), the FDA "raised questions . . . relating to certain findings observed in nonclinical animal toxicology studies" of lumateperone, the Company's proposed schizophrenia treatment.  Additionally, the FDA "requested additional information to confirm that the nonclinical findings are not indicative of a safety risk associated with long-term exposure in humans."

Following this news, on May 1, 2017, the price of Intra-Cellular Therapies' common stock fell by $3.33 per share, more than 24%, to close at $10.49 per share.

If you are an investor in Intra-Cellular Therapies and would like to discuss our investigation, please contact us by emailing pmayer@kaplanfox.com or by calling 800-290-1952. 

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Kaplan Fox & Kilsheimer LLP, with offices in New York, San Francisco, Los Angeles, Chicago and New Jersey, has many years of experience in prosecuting investor class actions. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at www.kaplanfox.com.  If you have any questions about this Notice, the action, your rights, or your interests, please contact:

Donald R. Hall
KAPLAN FOX & KILSHEIMER LLP
850 Third Avenue, 14th Floor
New York, New York 10022
(800) 290-1952
(212) 687-1980
Fax: (212) 687-7714
E-mail: dhall@kaplanfox.com